AzTrials
AzTrials

Acute Kidney InjuryNCT03047382

Electronic Alerting Tool to Help Prevent Acute Kidney Injury

A study testing AKI Care Bundle in people with Acute Kidney Injury, run by Western Sussex Hospitals NHS Trust at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Around a third of patients who develop acute kidney injury (AKI) do so after a hospital admission (hospital-acquired - HA-AKI). The primary aim of the study is to prospectively test whether introducing a complex intervention (a 'care package' - comprising a clinical prediction rule incorporating an electronic alert… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Kidney Injury
What is being tested?
AKI Care Bundle
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30,298 participants
Where
1 siteUnited Kingdom
Study dates
Jul 2014to Oct 2016
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Admission as an emergency
  • Spending at least one night as an in-patient

Who cannot join

  • Patients under 18
  • Patients not admitted as emergencies or staying less than one night in hospital.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • Western Sussex Hospitals NHS Foundation Trust

    Worthing, West Suusex

Other trials in United Kingdom

About this study

Official title: 'Preventable Acute Kidney Injury (AKI) Should Never Occur.' The Use of a Novel Electronic Prediction Alerting Tool to Deliver an Individualised Care Package for Hospital In-patients at Risk of AKI

Around a third of patients who develop acute kidney injury (AKI) do so after a hospital admission (hospital-acquired - HA-AKI).

The primary aim of the study is to prospectively test whether introducing a complex intervention (a 'care package' - comprising a clinical prediction rule incorporating an electronic alert which generates a checklist for patient management to relevant health professionals) can identify patients on admission to hospital who are at risk of developing HA-AKI, highlight the need for closer monitoring and allow putative preventative measures to be put in place.

The investigators will introduce the care package in one acute hospital and evaluate its effectiveness in reducing HA-AKI and its associated morbidity, over ten months, compared to a sister hospital within the same Trust (which will act as a control site). The investigators will extend evaluation for a further ten months to assess sustainability on the first site and introduce the package at the control hospital to assess generalisability. The primary aim is reducing HA-AKI, but secondary aims will include improved outcomes associated with HA-AKI, management of patients already with AKI on admission to hospital (whose care may also benefit from the checklist) and a cost-effectiveness analysis.

Read the detailed description

Acute Kidney Injury (AKI) is common in hospital (incidence of 10-20% - up to 70% in the critically ill), with high associated morbidity and mortality. Even small changes in renal function are associated with increased mortality. The 2009 National Confidential Enquiry into Patient Outcome and Death examined the care of patients who had died in hospital with a primary diagnosis of AKI. Over 40% of cases had an unacceptable delay in diagnosis and in 20% of cases, AKI was thought to be predictable and avoidable.

Electronic alerts have been studied for patients with established AKI, however, they have highlighted rises in creatinine after insult rather than identifying patients at risk of AKI - a third of hospital AKI cases occur after admission (HA-AKI). Risk factors have been reported in surgical and burns patients. However, strategies to identify patients admitted as medical emergencies at risk of developing AKI are lacking - the group accounting for most Intensive Care admissions with AKI.

The investigators multidisciplinary team, with significant experience utilising technology in healthcare, have developed a novel prediction score - Acute Kidney injury Prediction Score (APS). Utilising physiological measurements, biochemical parameters and known co-morbidities, the APS identifies patients at risk of developing HA-AKI following admission (1/3 of all AKI cases).

A 'care package' has been devised incorporating the APS into an automated electronic algorithm to send realtime alerts to staff on the Observation chart, e-mail the patient's Consultant and advise on a checklist. Alongside this, an E-learning AKI module for ward staff has been developed building on NICE Guidance with additional information regarding the APS.

Aims Primary: investigate whether introducing a 'care package' can reduce HA-AKI in patients admitted to hospital as an emergency.

Secondary include determining whether the intervention: reduces associated complications; improves outcomes in patients with AKI on admission; and is cost-effective.

Research Questions Primary: can a 'care package' by systematically recognising the 'at risk' patient, alerting and prompting management to staff educated in the problem, reduce HA-AKI?

Secondary:

  • Can harms associated with AKI be reduced?
  • Is the intervention acceptable to staff and are there barriers to implementation?
  • Are improvements sustainable and can the intervention be successfully applied to a second hospital?
  • Does the intervention improve outcomes of those with AKI on admission?
  • Is the intervention cost-effective?

Design A prospective, non-randomised, parallel cohorts study, with before-after trial periods, at intervention and control hospital sites, will be performed. A run-in phase (10 months) for baseline data collection and prospective external validation is followed by the intervention on one site (Worthing) with the Chichester site acting as control (Phase 1) for 10 months. The intervention will then be introduced at Chichester whilst continuing at Worthing (Phase 2) for 10 months. The additional period will allow analysis of the interventions' impact on readmissions.

Potential benefits:

  1. Preventing morbidity and mortality including secondary complications such as chronic kidney disease (immediate and longer term).
  2. Reducing length of stay, thus reducing potential exposure to harm.
  3. Prevent requirement for renal replacement therapies and escalation to Intensive Care with associated morbidity, mortality and psychological harm.
  4. A Cost-effectiveness analysis will aim to demonstrate whether such a strategy could provide savings locally and to the wider health economy (short and long-term).
  5. Inform the healthcare community on applicability of information technology to benefit patients and improve staff engagement, with potential utilisation in a number of other conditions.
Being tested
AKI Care Bundle
Medical subject headings
Acute Kidney Injury

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AKI Care BundleOther

    Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.

Study groups in NCT03047382
Study groupRoleWhat they receive
Worthing Hospital siteActive comparatorAKI Care bundle instituted at Worthing site
Receives: Other: AKI Care Bundle
Chichester Hospital siteNo interventionContinues standard care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Hospital Acquired AKI (HA-AKI) - KDIGO rise in serum creatinine

    HA-AKI will be defined as per KDIGO change in serum creatinine i.e. a ≥26.4μmol/L increase within a 48 hour period (during the first 7 days of admission to hospital) or a 1.5 times increase vs the admission result within the first 7 days of admission to hospital.

    Measured: <7 days from time of hospital admission

Secondary outcomes (5)
  1. Admission to Intensive Care Unit (ICU)

    Patients who have been admitted to a ward bed who then have care escalated to ICU.

    Measured: At any time point during the admission under analysis i.e. from admission to either discharge from the hospital or death in-hospital, participants will be followed for the duration of hospital stay, expected average of 7 days.

  2. Mortality

    Measured: During the index hospital admission. Each participant will be followed for the duration of hospital stay, an expected average of 7 days.

  3. Mortality associated with AKI on admission

    AKI on admission defined as at least 1.5 times baseline serum creatinine or ≥354μmol/L without a baseline. Baseline defined using NHS algorithm.

    Measured: During the index hospital admission. Each participant will be followed for the duration of hospital stay, an expected average of 7 days.

  4. Magnitude of acute deterioration in Creatinine

    This will be measured in both KDIGO stage: increase from Stage 1 to Stage 2 (200% increase in serum creatinine) or Stage 3 (300% increase in serum creatinine) and also peak mean increase in serum creatinine.

    Measured: From admission to peak creatinine within the first 7 days of the index admission.

  5. Requirement for renal replacement therapies

    Whether patients (not normally on dialysis) require RRT during the index admission or not.

    Measured: During the hospital admission. During the index hospital admission. Each participant will be followed for the duration of hospital stay, an expected average of 7 days.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Feb 2017 (estimated)
  2. Study startJul 2014
  3. Primary completionApr 2016
  4. Study completionOct 2016

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30,298 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03047382
Sponsor's protocol ID
13/LO/0960
Status last verified
Apr 2016
First submitted
1 Sep 2015
Last updated
9 Feb 2017
Results posted
No
Data monitoring committee
No

Publications

  • Hodgson LE, Roderick PJ, Venn RM, Yao GL, Dimitrov BD, Forni LG. The ICE-AKI study: Impact analysis of a Clinical prediction rule and Electronic AKI alert in general medical patients. PLoS One. 2018 Aug 8;13(8):e0200584. doi: 10.1371/journal.pone.0200584. eCollection 2018.

    PubMed 30089118

Questions about this trial

What is this clinical trial studying?

A study testing AKI Care Bundle in people with Acute Kidney Injury, run by Western Sussex Hospitals NHS Trust at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Feb 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Hospital Acquired AKI (HA-AKI) - KDIGO rise in serum creatinine (time frame: <7 days from time of hospital admission). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03047382, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in